ストックスクリーナーアプリを入手
2.755
1.66%
0.045
前日終値:
$2.71
開ける：
$2.67
24時間の取引高:
207.30K
Relative Volume:
0.36
時価総額：
$287.34M
収益：
$45.44M
当期純損益:
$-35.43M
株価収益率:
-8.1029
EPS:
-0.34
ネットキャッシュフロー:
$-25.39M
1週間 パフォーマンス:
-0.90%
1か月 パフォーマンス:
-17.51%
6か月 パフォーマンス:
-26.34%
1年 パフォーマンス:
-32.97%
1日の値動き範囲:
$2.63
$2.785
1週間の範囲:
$2.62
$2.90
52週間の値動き範囲:
$2.62
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
MXCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.755 | 287.34M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
131.78 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.18 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.30 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.68 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.84 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-29 | 開始されました | Craig Hallum | Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | BTIG Research | Buy |
| 2021-08-24 | 開始されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | Stephens | Overweight |
| 2021-08-24 | 開始されました | Stifel | Buy |
| 2021-08-24 | 開始されました | Wedbush | Outperform |
| 2021-08-24 | 開始されました | William Blair | Outperform |
すべてを表示
Maxcyte Inc (MXCT) 最新ニュース
MaxCyte Expands Capital with New Stock Issuance - TipRanks
MaxCyte stock plunges to 52-week low, touches $2.75 - Investing.com
MaxCyte CFO completes RSU vesting and tax-related sale By Investing.com - Investing.com Australia
MaxCyte CFO completes RSU vesting and tax-related sale - Investing.com India
MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
MaxCyte executives receive equity incentives By Investing.com - Investing.com South Africa
MaxCyte executives receive equity incentives - Investing.com India
MaxCyte Awards Stock Options and Units to Executives - TipRanks
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock - Investing.com India
Maxcyte general counsel David Sandoval sells $1,122 in stock - Investing.com
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock - Investing.com
BlackRock Increases Stake in MaxCyte to 7.71% - TipRanks
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha
What is William Blair’s Estimate for MaxCyte Q1 Earnings? - Defense World
US Bancorp DE Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - Defense World
MaxCyte files annual report with SEC By Investing.com - Investing.com Australia
MaxCyte core business revenue grows despite overall decline By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 - Investing.com
MaxCyte stock touches 52-week low at $3.11 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock touches 52-week low at $3.11 amid market challenges - Investing.com Australia
MaxCyte’s Promising Financial Outlook and Strategic Growth Justify Buy Rating - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey
MaxCyte price target lowered to $6 from $8 at BTIG - TipRanks
MaxCyte stock price target cut to $6 at BTIG By Investing.com - Investing.com South Africa
MaxCyte price target lowered to $9 from $11 at Stifel - TipRanks
MaxCyte stock price target cut to $6 at BTIG - Investing.com India
MaxCyte files annual report with SEC - Investing.com India
MaxCyte core business revenue grows despite overall decline - Investing.com India
Maxcyte Sees 2025 Core Revenue To Grow 8% To 15% - Marketscreener.com
MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates By Investing.com - Investing.com Australia
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte’s Strategic Expansion and Financial Resilience Drive Buy Rating - TipRanks
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates - Investing.com India
MaxCyte reports Q4 EPS (10c), consensus (12c) - TipRanks
MAXCYTE, INC. SEC 10-K Report - TradingView
Maxcyte Inc (MXCT) 財務データ
収益
当期純利益
現金流量
EPS
Maxcyte Inc (MXCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.44%
0.15%
大文字化:
|
ボリューム (24 時間):